Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
NCT03436732 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2019-11-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to fatal occurrence (pneumonitis) attributed to one of the study drugs.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MSLN within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-07-17Results posted on the registry: Bayer, Anetumab ravtansine (BAY94-9343) + Vinorelbine (NCT02610140)
- 2020-05-15Results posted on the registry: Mayo Clinic, Anetumab Ravtansine + Atezolizumab (NCT03455556)
- 2020-03-17Results posted on the registry: Morphotek, Placebo + Amatuximab (NCT02357147)
- 2020-03-17Also stopped (terminated): Morphotek, Placebo + Amatuximab (NCT02357147)
- 2019-12-17Also stopped (terminated): National Cancer Institute (NCI), Amatuximab (MORab-009) (NCT01413451)
- 2019-05-21Results posted on the registry: National Cancer Institute (NCI), Anetumab Ravtansine (NCT02839681)
- 2019-05-21Also stopped (terminated): National Cancer Institute (NCI), Anetumab Ravtansine (NCT02839681)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision